SynthesisBMC psychiatry2026
The role of vascular endothelial growth factor (VEGF) in major depressive disorder: an update meta-analysis.
Synthesis in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMajor depressive disorder (MDD) is a prevalent mental health condition characterized by persistent feelings of profound sadness, emptiness, or hopelessness, as well as a marked loss of interest or pleasure in almost all activities. Evidence indicates that vascular endothelial growth factor (VEGF) is essential for neuronal survival, angiogenesis, and synaptic connectivity, and is also involved in stress resilience and antidepressant mechanisms, offering new perspectives on the pathophysiology of MDD. Although several studies have examined the relationship between peripheral VEGF levels and MDD, their findings remain inconsistent or inconclusive. Therefore, this updated meta-analysis was conducted to clarify the role of VEGF in the etiology of MDD.
objectiveThis study aimed to conduct an updated meta-analysis to investigate the relationship between plasma VEGF levels in patients with MDD compared to healthy controls (HCs).
methodsFour databases, PubMed, Embase, Cochrane, and Web of Science, were systematically searched for the meta-analysis from their inception until December 2024. A total of 14 case-control studies involving 2,919 participants (1,256 patients with MDD and 1,663 HCs) were included. The meta-analysis utilized both the ratio of means (RoM) and the standardized mean difference (SMD) methods to enhance interpretability and clinical relevance.
resultsThe meta-analysis confirmed that patients with MDD had significantly higher VEGF levels compared to HCs (RoM = 1.21, 95% CI: 1.06-1.38, p < 0.001; SMD = 0.45, 95% CI: 0.13-0.77, p < 0.001).
conclusionThe findings suggest that elevated plasma VEGF levels are associated with MDD, as indicated by the updated meta-analysis. A potential biological link between VEGF and MDD exists, offering important insights into the underlying pathophysiological mechanisms. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
42458396What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.